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Abstract

Finasteride is currently approved and largely used as a therapeutic option for androgenetic
alopecia. Apparently a safe drug and effective at the onset of its application, several concerns
have since appeared over the years regarding the frequency and magnitude of finasteride adverse
effects, which in some cases appear irreversible even after drug termination.
This paper discusses the use of finasteride for androgenic alopecia from two distinct
perspectives. On the one hand, androgenic alopecia is a condition that especially affects a person’s
self-image and esteem, aspects that are subjectively-constructed and thus relative and changeable.
On the other hand, this condition involves a multifactorial etiology, with androgens being only
partly responsible. Because androgens have important and unique physiological roles within the
body, any procedure that results in androgenic suppression should be advised with caution.
Furthermore, adverse effects induced by finasteride are neither fully documented nor easily
treated. Finally, as alternative therapeutic approaches (such as topical finasteride) become
available, the oral administration of finasteride for androgenic alopecia should, in our opinion, be
reevaluated. Due to such concerns, a detailed and informed discussion should take place with
patients considering therapy with finasteride for androgenic alopecia.
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Highlights

✓ Finasteride administration places the subjects with androgenic alopecia into an abnormal

state, characterized by a low level of DHT
✓

Finasteride adverse effects persist in some men indefinitely after treatment cessation, the
corresponding medical support being non-specific, namely symptomatic
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Introduction

most adequate therapy is not straightforward. This paper
Androgenetic alopecia (AGA) is not considered an continues a series of articles focused on finasteride
effective disease, as it has minimal or no impact on body administration for androgenic alopecia that better
physiology. However, it is currently accepted as a evaluate the opportunity of long term use of an oral
relatively benign affection that not only has a chemical compound for a biological condition having
psychological impact but also has variable psycho- non-life-threatening implications.
social implications. Some individuals adapt well to
AGA, while others seem to be severely disturbed, the
condition being associated with decreased self-esteem,
stress, and even depression (1). Depending on
geographic region and culture, bald people are
sometimes perceived by others as less attractive and
older (2). Studies performed on patients with hair loss
have shown that younger individuals and those with
longer duration of AGA are generally more severely
affected regarding self-esteem and social perception (3).
Various therapeutic approaches for AGA have been
proposed and tested in clinical practice, with topical
minoxidil and oral finasteride both currently approved
by the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) as treatment
options. Before beginning therapy, patients must be
advised that ongoing administration is required in order
to achieve and maintain therapeutic benefits on hair loss
(4).
Other therapeutic strategies have been also tested,
some positive results being observed with Alfatradiol
(17-α-estradiol),
ketoconazole, and

latanoprost,
various

bimatoprost,

topical reagents (5).

Furthermore, recent studies with platelet-rich plasma
(alone or in combination with minoxidil) seem
promising in the management of AGA (6).

A surgical

approach toward AGA includes autologous hair
transplantation using hair follicles especially from the
occipital area. For both men and women, predicted
results are generally considered acceptable; however
this procedure can be performed only by an experienced
surgical team. Moreover, implantation of prosthetic hair
is associated with some (non-negligible) adverse effects
(7). For women with AGA, the use of several drugs such
as cyproterone acetate, spironolactone, and flutamide
have been investigated. Such compounds have shown
only modest results in ameliorating AGA, a better effect
being obtained in women with hyperandrogenism (8).
All therapeutic solutions presented above have
variable adverse effects and relatively limited results
(which can be maintained only through ongoing
administration of the drug), so that the choice of the

Discussion

Inhibitors of the 5α-reductase enzyme such as
finasteride and dutasteride are currently approved and
administered for benign prostatic hyperplasia, while for
androgenic alopecia these same compounds are the
subject of controversy in the literature. Several studies
suggest that finasteride should be used with caution for
AGA due to the considerable adverse effects induced in
some men (9). These adverse effects are the
consequence of the action of finasteride in decreasing
the conversion of testosterone into the more potent
metabolite, dihydrotestosterone (DHT), a natural
compound that plays a critical role in the process of
growth and maintenance of several functions of tissues
and organs (thereby modulating important biochemical
signaling pathways of human physiology). In support of
this idea, testosterone deficiency, for example, is a
recognized medical condition with a specific
symptomatology. Administration of exogenous
testosterone in hypogonadal men leads to correction of
the plasmatic level of testosterone, which often is
followed by amelioration and subsequent disappearance
of the symptomatology (10).
Inhibitors of 5α -reductase enzyme therefore have
the potential to induce a veritable hypogonadal status,
yet in turn, the same 5α -reductase inhibitors have the
capacity to
ameliorate
androgenic
alopecia.
Accordingly, administration of finasteride and
dutasteride for androgenic alopecia might be viewed in
two very different ways. Taking into account only its
therapeutic efficiency for AGA, several authors have
demonstrated that dutasteride (a stronger inhibitor/ more
potent antiandrogen than finasteride) produces superior
results in ameliorating androgenic alopecia than
finasteride, such that it should be preferred in clinical
practice for AGA (11).
In contrast, from the perspective of drug safety and
adverse effects, other authors have resisted the use of
dutasteride and, further, suggest that oral finasteride
should be replaced with topical administration. Studies
have shown that both scalp and plasma DHT levels
significantly decrease after topical application of
finasteride, while no changes of testosterone levels were
registered in plasma. In all studies investigating topical
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finasteride, significant decreases in the rate of hair loss of the drug being able to explain many finasteride side
and increases in total and terminal hair counts (4) were effects, like mental and sexual impairment.
noted.
Finasteride (administered orally) is extensively
metabolized
by cytochrome P450 in the liver, the
1. Pharmacology of finasteride
Generally, inhibition of the 5α-reductase enzyme by resulting metabolites having (comparable to finasteride)
this drug disrupts the conversion of testosterone to DHT, no more than 20% inhibitory activity. Oral
resulting in a decrease in serum DHT levels by about 65- administration of finasteride produces a significant
70%. Thus, finasteride does not completely suppress decrease of plasmatic DHT concentrations during the
DHT production because it lacks significant inhibitory first 6-8 hours, and this effect persists for about 24 hours
effects on the 5α-reductase type I isoenzyme, the main for a single dose, and longer for repeated
inhibitory effect being on the type II and III isoenzymes. administrations. Daily administration of finasteride
In fact, the action of the 5α-reductase enzyme is more suppresses the serum DHT level by about 65-70%,
complex, intervening in the metabolism of multiple depending on the dose.
Excretion is largely realized as metabolites through
neurosteroids within the brain (e.g., testosterone,
progesterone,
deoxycorticosterone,
etc.),
neuromodulators that further interfere with cerebral
activation of GABAA receptors (12). By inhibiting the
5α-reductase enzyme, finasteride leads to several
hormonal abnormalities and GABA disruption, with
important implications on various neurophysiological
processes of the brain. Such interference is encountered
not only during finasteride administration but also after
treatment cessation, which is clinically expressed as the
post-finasteride syndrome. Men with post-finasteride
syndrome present—at considerable periods of time after
the therapy termination ranging from months to years—
disturbed levels of specific neurosteroids in
cerebrospinal fluid and plasma, including: increased
testosterone, pregnenolone, 5a-androstane-3a, 17b-diol,
and decreased progesterone, dihydroprogesterone,
dihydrotestosterone, and allopregnanolone (13).
After finasteride administration, circulating levels
of testosterone and estradiol slightly increase (by up to
15%), remaining however within the physiologic range,
though qualified by the fact that testosterone is much
less active than DHT, which decreases significantly.
Similar variation has been observed for luteinizing
hormone and follicle stimulating hormone, which
increase by about 10% during finasteride administration
though without exceeding physiological levels.
Finally, studies show that finasteride action is more
complex than initially assumed, inhibiting not only 5αreductase but also competitively inhibiting the 5βreductase (AKR1D1) and other possible enzymes (14).
Oral administration of finasteride is not affected by
food, having a good absorption and a bioavailability
around 65%. The maximum plasmatic concentration is
reached about 1-2 hours after administration, successive
doses leading to a slow accumulation of the drug, with
plasma protein binding of finasteride being about 90%.
finasteride crosses the blood-brain barrier, this capacity

urine (about 39%) and feces (57-60%). The mean
terminal half-life of finasteride is about 7 hours, shorter
in younger men and longer in men over 70 years (15).
2.

Adverse effects of finasteride
Finasteride side effects are the consequence of

cerebral interferences of this drug with sexual
neuromodulators and GABAA receptors, although a
direct action of finasteride on cerebral receptors cannot
be excluded. Such adverse effects described in the case
of finasteride can be absent or negligible (anhedonia,
lack of mental concentration, insomnia, chronic fatigue,
elevated body mass index), or in contrast, quite severe
(depression, suicidal ideations, impotence, erectile
dysfunction, decreased libido, ejaculation disorders)
(16, 17).
Due to interference with GABAA receptors,
finasteride seems to change tolerance to ethanol in some
individuals, with former users of finasteride reporting a
variable decreasing tolerance to alcohol (18). Other
studies have reported possible connections (if not causal
relationships) between finasteride administration and
the occurrence of different forms of neoplasia, such as
high-grade prostate cancers or male breast cancer (19,
20). If finasteride is administered to early pregnant
women, contraception should be taken into account due
to a potential embryoteratogenic effect, while in
postmenopausal women finasteride seems to be
effective only at high doses (21).
Finally, hormonal disturbances and GABA
interferences from finasteride are encountered not only
during the drug administration but also after treatment
cessation in some patients, with corresponding clinical
manifestations in the form of the so-called postfinasteride syndrome. The most frequent manifestations
of post-finasteride syndrome are relatively similar with
finasteride side effects occurring during drug
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administration, being represented especially by
mental/psychological impairments and sexual disorders.
3. Inconsistent adverse effects of finasteride
Recent studies suggest that the main (mental and
sexual) side effects of finasteride would be encountered
only in a subset of men, according to structural and
informational dichotomies of the brain. These two
neuro-physiological processes of the brain are
presumably interrelated with hand preference and sexual
orientation in both men and women (22-24).
Informational dichotomy of the brain is closely
related to two distinct and opposite cerebral networks
(task positive network and default mode network),
sexual hormones acting on the concrete mind while
sexual pheromones preferentially activating the abstract
mind (25). Structural dichotomy of the brain results
from the lateralization process of the brain, with
androgens and female pheromones activating the left
hemibrain, and estrogens and male pheromones
activating the right hemibrain (26, 27).
According to this line of thinking, finasteride
adverse effects would be encountered most strongly in
right-handed persons who present a concrete-thalamic
psycho-physiologic profile. In contrast, left-handed men
with a concrete-thalamic profile would be less likely to
develop side effects.
Thus, hand preference and psychological profile/

roles within the body, and its suppression should be
carefully advised. As an example, recent studies show
that 5α-reductase-2 deficiency leads to reduced
dominance-related and impulse-control behaviors (28).
In addition, studies using functional magnetic resonance
imaging show that men with post-finasteride syndrome
(consisting of sexual dysfunctions and major
depression) revealed abnormal function in brain
connectivity (29).
• More importantly, adverse effects induced by
finasteride are incompletely documented. In support of
this point, mental and sexual functions, generally
affected in tandem by finasteride, lead to specific
disorders such as sexual dysfunctions and depression,
which may potentiate one other and which do not
respond well to established/ etiological treatments.
Furthermore, the post-finasteride syndrome itself has yet
to be fully elaborated (17).
• Adverse effects from finasteride have generally been
investigated only over relatively short periods of time.
Important additional data are needed to understand
potential metabolic implications that might develop 510 years after finasteride cessation.
• Study design and procedures should also be
revisited. For example, the frequency and magnitude of
finasteride adverse effects strongly depend on the study
protocol, being higher when patients are advised (before
sexual orientation could be used as possible predictive the therapy) of possible adverse effects, and lower (or
factors for finasteride side effects, being therefore able ignored) when the patients are not advised (30).
to delineate, prior to treatment, patients having a lower

risk for developing sexual side effects to the drug. For • Alternative therapeutic approaches are becoming
available, such as topical application of finasteride
those men with androgenic alopecia having a lower
which bypasses the liver (toxicity) and which results in
predicted risk for adverse effects, the use of finasteride
higher concentrations in the scalp skin at low doses than
would be presumed safe (7).
oral administration.
4. The risk-benefit ratio of finasteride administration
• Finally, androgenic alopecia is a condition that can
in androgenic alopecia
affect one’s self-image and esteem, aspects that are
To appreciate the risk-benefit ratio of finasteride
subjective/ relative and thus changeable over time.
administration on patients with androgenic alopecia, it
Contrary to this perspective, a possible post-finasteride
is first necessary to establish the major elements that
syndrome could persist indefinitely in time, and subjects
influence the evaluation.
must be informed before therapy about these aspects.
• First, male androgenic alopecia is a benign condition
with a multifactorial etiology, being only in part

Conclusions

induced/ supported by DHT. Other non-hormonal co-

Although not an exhaustive presentation, here we
factors are also involved, as those with androgenic attempted to highlight the importance of patient
alopecia actually have a normal (non-elevated) level of informing and consent before commencing therapy with
DHT. Thus, finasteride administration places subjects finasteride for androgenic alopecia. Generally, men who
with androgenic alopecia into an abnormal state, seek medical support for androgenic alopecia seem to be
characterized by a low level of DHT.
more emotionally distressed than others, while adverse
• DHT, the most active androgenic compound, has its effects occurring in those with post-finasteride
own (neuro-endocrine, metabolic, etc.) physiological syndrome can persist indefinitely in time.
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